MetaTech and CM Plus Establish Strategic Partnership to Build “AI Katana” Platform for Biotech Market Expansion in Japan and Asia
The partnership will integrate MetaTech’s advanced AI-driven GMP document generation technology with CM Plus’s established regulatory and virtual pharmaceutical capabilities in Japan. Together, the two companies aim to provide a comprehensive, high-efficiency support system for pharmaceutical and biotech firms seeking to enter each other’s markets, while also expanding into broader Asian markets.
This collaboration carries both strategic and symbolic significance. CM Plus’s founder and Group CEO, Mr. Tsunehiro Togashi, is a descendant of a 14th-generation samurai family. MetaTech’s proprietary AI platform, named “Neo-Katana,” symbolizes the precision and power of an AI “blade” capable of solving complex GMP documentation challenges with speed and accuracy. The fusion of samurai heritage with cutting-edge AI technology reflects a unique cross-cultural partnership that is both strategic and emblematic.
Under the MOU, both parties will jointly promote their systems focusing on regulatory compliance, GMP documentation, and international market expansion. MetaTech’s AI platform — the first in Taiwan to build a full GMP data model — enables automatic generation of compliant documents, holding algorithm patents in Taiwan and provisional patents in the U.S., Japan, and Europe.
CM Plus, Japan’s first licensed “Virtual Pharmaceutical Company,” provides plant engineering, GMP qualification, and regulatory consulting to guide overseas biotech products through Japan’s approval pathway. The collaboration will also integrate CM Plus’s pharmo.AI regulatory engine and CORRESSA project management system with MetaTech’s AI documentation platform to enhance data integrity and compliance efficiency.
Through this alliance, MetaTech and CM Plus will serve as each other’s exclusive partners in their home markets. MetaTech will support Japanese biotech firms entering Taiwan, while CM Plus will represent MetaTech in Japan and explore opportunities across Southeast Asia.
This MOU marks a strategic alignment between Taiwan’s leading AI biotech innovator and Japan’s premier regulatory service provider, creating a new model for AI-powered GMP and cross-border cooperation in Asia’s biotech industry.
